tbuckley/cabot-search huggingface dataset:
Über Homosexualität: Ein Beitrag zu einer medizinischen Anthropologie.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PDTM-31. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG
Authors: Alan Mackay, Diana Carvalho, Valeria Molinari, Helen Pemberton, Sara Temelso, Anna Burford, Matthew Clarke, Mariama Fofana, Jessica Boult, Elisa Izquierdo, Katy Taylor, Lynn Bjerke, Janat Fazal Salom, Ketty Kessler, Rebecca Rogers, Lynley Marshall, Fernando Carceller, Jane Pears, Andrew Moore, Evelina Miele, Andrea Carai, Angela Mastronuzzi, Simon Robinson, Chris Lord, Nagore Olaciregui, Jaume Mora, Angel Montero Carcaboso, Darren Hargrave, Maria Vinci, Chris Jones
Journal: Neuro-Oncology (2018)

Paediatric high grade glioma and diffuse midline glioma (including DIPG) are comprised of multiple biological and clinical subgroups, the majority of which urgently require novel therapies. Patient-derived in vitro primary cell cultures represent potentially useful tools for mechanistic and preclinical investigation based upon their retention of key features of tumour subgroups under experimental conditions amenable to high-throughput approaches. We established 21 novel primary cultures derived from patients in London, Dublin and Rome, and together with cultures shared from Barcelona, Brisbane and Stanford we assembled a panel of 42 models under 2D (laminin matrix) and/or 3D (neurospheres) conditions, fully credentialed by phenotypic and molecular comparison to the original tumour sample (methylation BeadArray, panel/exome sequencing, RNAseq). Screening against a panel of ~400 approved chemotherapeutics and small molecules, we identified specific dependencies associated with tumour subgroups and/or specific molecular markers. This allowed for functional annotation of distinct variants in human tumours, for example cells with sensitizing (HSJD-GBM-001, PDGFRA_A385ins; HSJD-DIPG-008, PDGFRA_D846N) or resistance (HSJD-GBM-002, PDGFRA_D842Y) mutations to a range of PDGFRA inhibitors. We found individual models showing profound sensitivity to distinct kinase inhibitors based upon cell-specific mechanisms of activation, such as QCTB-R006 to multiple FGFR-targeted drugs, and HSJD-DIPG-012 to those directed against EGFR. Subclasses with functionally relevant pathway-based dependencies included sensitivity of DIPGs with PPM1Dmutation (HSJD-DIPG-008, HSJD-DIPG-014) to PARP and MDM2 inhibitors, and MAPK-dysregulated PXA-like cultures (ICR-CXJ-008, ICR-CXJ015) differentially responsive to inhibitors of upstream signalling viaPKC and CK2. Of note, all cultures were insensitive to temozolomide. In total, 85% cells were found to have at least one drug screening hit in short term assays linked to the underlying biology of the patient’s tumour, providing a rational approach for individualised clinical translation.
MEDICAL PREPAREDNESS
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reprint of "Nanobody — Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting"
Authors: Marina Talelli, Cristianne J.F. Rijcken, Sabrina Oliveira, Roy van der Meel, Paul M.P. van Bergen en Henegouwen, Twan Lammers, Cornelus F. van Nostrum, Gert Storm, Wim E. Hennink
Journal: Journal of Controlled Release (2011)
STOKES-ADAMS DISEASE.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tritium Assay by Liquid Scintillation Spectrometry
Authors: JACK LEIBMAN, FRANK A. GOTCH, ISIDORE S. EDELMAN
Journal: Circulation Research (1960)

Data have been presented which indicate that the liquid scintillation spectrometer provides a convenient and accurate method for the assay of tritium in body fluids. By means of arterial disappearance curves and comparative measurements of concentrations in plasma, transudates, and cerebrospinal fluid from 1 to 6 hours after simultaneous injection, the distribution rates of tritiated water were compared to those of deuterium oxide. No significant difference was found in the behavior of these tracers under the conditions of this study. It is concluded, therefore, that THO and D 2 O are equally reliable for studies on the kinetics of water distribution and for the measurement of total body water.
Colloidal Gold for the Lange Test. Correction
Journal: BMJ (1923)

DR. HENRY WALDO (Clifton, Bristol) asks for advice as to the most suitable parts of Englaind for a male patient, aged about 50, to live, with more or less persistent anaemia.INCOME TAX."J. C." has been assessed separately for his remuneration as coroner.** We understasd that the Board of Inland Revenue have no objection to salaries for stuch appoisstments being included with the general earnings of a me(lical practitiouier in one sum for assessment under Schedule D; "J.C." might point this out to the local iuspector.Allewances made voluntarily by relatives are not chargeable to tax on the recipient.Allowance can be claimed for the cllildren (otn the form of
VACCINATION OF THE NEW-BORN AGAINST TUBERCULOSIS WITH BACILLUS CALMETTE GUÉRIN
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tinkering with the Tinkerer: Pollution versus Evolution
Authors: Glen A. Fox
Journal: Environmental Health Perspectives (1995)

Pollutants can act as powerful selective forces by altering genetic variability, its intergenerational transfer, and the size, functional viability, adaptability, and survival of future generations.It is at the level of the cell and the individual that meiosis occurs, that genetic diversity is maintained, and behav- ior, reproduction, growth, and survival occur and are regulated.It is at this level that evolutionary processes occur and most pollutants exert their toxic effects.Chronic exposure to chemicals contributes to the cumulative stress on individuals and disrupts physiological processes and chemically mediated communication thereby threatening the diversity and long-term survival of sexually reproducing biota.Regional or global effects of pollu- tion on the atmosphere, hydrosphere, and lithosphere have indirectly altered Earth's life-support systems, thereby modifying trace metal balance, reproduction, and incidence of UV-B-induced DNA damage in biota.By altering the competitive ability and survival of species, chemical pollutants potentially threaten evolutionary processes and the biodiversity and function of intercepting ecosystems.
PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM
Authors: Bryan Li, Alexandre Vasiljevic, Christelle Dufour, Ben Ho, Eugene Hwang, Sridharan Gururangan, Jordan Hansford, Annie Laquerriere, Marie-Bernadette Delisle, Jason Fangusaro, Fabien Forest, Nobusawa Sumihito, Helen Toledano, Diane Birks, Xing Fan, Maryam Fouladi, Amar Gajjar, Guillaume Gauchotte, Lindsey Hoffman, Chris Jones, Delphine Loussouarn, Karima Mokhtari, Scott Pomeroy, Audrey Rousseau, Gino Somers, Michael Taylor, David S Ziegler, Mei Lu, Cynthia Hawkins, Richard Grundy, Anne Jouvet, Eric Bouffet, D Ashley Hill, Annie Huang
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Pineoblastoma (PB) is a rare but aggressive pediatric brain tumour arising from the pineal gland. Overall survival rates are estimated at 50–70%, with younger patients (&lt; 5 years old) faring much worse (15–40%) despite intensive treatment regimens. Although germline RB1 and DICER1 alterations have been reported in a small proportion of PB, the clinical significance of such alterations and the biology of sporadic cases remains unknown. METHODS We collected tumor tissue from 93 PB cases diagnosed at their referring centres. We undertook global DNA methylation profiling and performed multiple orthogonal consensus clustering analyses to elucidate PB subgroups. Chromosomal copy number alterations were determined using Conumee and GISTIC2, and whole exome or targeted sequencing was completed. Clinical data was analyzed with correlative statistical methods and outcomes were measured by Kaplan-Meier survival estimates. RESULTS PB comprise five epigenetic groups, designated 1, 2, 3, 4A, and 4B. Deleterious, mutually exclusive alterations affecting miRNA biogenesis pathway members (DICER1, DROSHA, and DGCR8) were observed in 12/21 group 1 and 11/11 group 2 samples. Group 4A was characterized by recurrent RB1 loss and gain of the oncogenic miR-17/92, and group 4B by recurrent gain or amplification of MYC. These groups also exhibit distinct clinical features. PB groups 1–3 arose in older children (median ages 5.2–14.0 years) and had intermediate to excellent outcome (5-year OS of 71.9–100%). Group 4A and 4B were restricted to much younger children (median age 1.3–1.4 years) and had dismal prognoses (5-year OS 37.5% and 28.6%, respectively). CONCLUSIONS PB divides into five groups with distinct genetic and clinical profiles. These findings will have important implications for precise patient stratification and form the foundation for preclinical studies of biology-informed therapies.
Stem cell factor restores hepatocyte proliferation in IL-6 knockout mice following 70% hepatectomy
Authors: Xiaodan Ren, Cory Hogaboam, Audra Carpenter, Lisa Colletti
Journal: Journal of Clinical Investigation (2003)

Stem cell factor (SCF) is a molecule with known proliferative effects on hematopoietic cells. More recent studies suggest that this molecule may also have effects on cellular differentiation and proliferation in other types of cells. The current investigations demonstrate that there is a large reservoir of SCF in the liver, that hepatic SCF levels change dramatically following partial hepatectomy in mice, and that SCF blockade, either by administration of anti-SCF antibodies or by using genetically altered, SCF-deficient mice, inhibits hepatocyte proliferation after partial hepatectomy; if SCF is replaced in the genetically SCF-deficient mice after partial hepatectomy, hepatocyte proliferation is restored to that seen in WT animals. Furthermore, SCF administration to IL-6 knockout mice also restores hepatocyte proliferation to normal. In vitro studies using primary mouse hepatocytes demonstrate that SCF causes hepatocyte proliferation and is induced by IL-6 and that treatment with anti-SCF antibodies inhibits IL-6–induced hepatocyte proliferation. Further in vivo studies in IL-6 knockout mice demonstrate that SCF administration to these animals increases p-stat3 levels, suggesting that the SCF-induced increase in hepatocyte proliferation in this system is stat3-mediated.
Mind and Its Disorders. A Text-Book for Students and Practitioners of Medicine.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fertility Consultation
Authors: Woods Nash
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ECT and memory loss: the debate goes on
Authors: E. R. Gonzalez
Journal: JAMA (1979)

For nearly two hours in Chicago recently, psychiatrists from all over the world discussed electroconvulsive therapy (ECT). It is the most effective and satisfying treatment for severe depression, said Gary Aden, MD, of San Diego, despite the abuse that has been heaped on it by critics. It can be used as an ongoing prophylactic treatment, said William Karliner, MD, of Scarsdale, NY, who has used "maintenance ECT" extensively for the prevention of psychotic relapses. Others emphasized that ECT averts the side effects of pharmacotherapy, notably neuroleptic-induced tardive dyskinesia; that it is helpful for adolescents who do not respond rapidly to antipsychotics; and that it does not have to be given in the standard dosage of three seizures per week. Rather, it can be administered at the rate of four to six seizures per week, or even eight seizures in one or two sessions. "I would not give up on an
THU0316 Update on the juvenile systemic sclerosis inception cohort. www.juvenilescleroderma.com
Authors: I. Foeldvari, C. Ehlers, C. Len, M.M. Katsicas, A. Tae, T. Kalinich, I. Kone-Paut, L. Mouthon, Y. Uziel
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile systemic sclerosis (jSSc) is a rare autoimmune disease. Currently just retrospective data exist without a standardized assessment of the organ involvement. Our project is the first projects, where prospectively and with a standardized assessment data of early jSSc patients are collected. <h3>Objectives</h3> To learn about the evolvement of juvenile systemic sclerosis <h3>Methods</h3> Using the proposed standardized patient assessment protocol patients with early jSSc, entry into the cohort within the first 24 months of disease, are prospectively assessed. All participating centres approved the protocol over the own IRB. <h3>Results</h3> 50 centers from 20 countries applied to participate on the project. The assent and consent forms were translated into the local native languages. Up till now 16 patients were enrolled, who fulfilled the inclusion criteria. The mean follow up of the patients in the cohort are 1.9 years. 12 of the 16 patients were female. The age of onset of Raynaud symptomatic were 13.1 years The mean age at the onset of the non-Raynaud symptomatic were 13.2 years. Age at diagnosis at diagnosis was 13.5 years. 11 of the 16 have diffuse subtype, 5 of them have an overlap symptomatic. alle were ANA positive, and 6 of them were anti-Scl 70 positive. None of them was anticentromere positive. 15 of them have Raynaud’s. None had renal crisis. <h3>Conclusions</h3> We present the data on the first 16 prospectively assessed patients with jSSc. The current recruitment data confirms that pediatric patients are different from the adult patients. A large number of patients show overlap feutures. We are only at the first phase of this project and hope to recruit up to 50 patients and follow them prospectively over the next 2 to 4 years at least. <h3>Disclosure of Interest</h3> None Declared
Determinants of brachial artery endothelial function in women: pilot phase results from the WISE clinical centers
Authors: R. Holubkov, S.P. McGorray, S.E Reis, N. Reichek, W.J. Rogers, B.L. Sharaf, G. Sopko, S.F. Kelsey, C.N.Bairey Merz, C.J. Pepine
Journal: Journal of the American College of Cardiology (1998)
PWE-253 Feasibility study: a randomised controlled trial of standard closure of stoma site versus biologic mesh reinforcement
Authors: ROCSS Trial Management Group
Journal: Gut (2015)

<h3>Introduction</h3> Hernia formation at the site of a previous stoma occurs in up to 30% of patients, 50% of whom are subject to complex re-operation. This paper reports the phase II randomised feasibility study of prophylactic reinforcement of closed stoma sites using biologic mesh, representing a novel surgical technique using a novel implantable device. <h3>Method</h3> Multicentre, patient and assessor blinded, randomised controlled trial aiming to recruit 560 patients, delivered though trainee research collaboratives working within existing surgical networks. An initial internal feasibility study of 90 patients aimed to test early safety and deliverability of the surgical technique implemented across multiple sites simultaneously. <h3>Results</h3> The feasibility study recruited 90 patients from 104 patients approached (92%), three months ahead of schedule. 90% of participating centres randomised patients within 30 days of opening. Overall, 41.1% of stomas were created for a malignant indication (versus benign, 37/90) and 73.3% were ileostomies (versus colostomy, 66/90). No mesh-specific complications were reported. One mesh was removed for access to the abdominal cavity, unrelated to the mesh itself. Independent Data Monitoring Ethics Committee review of un-blinded adverse event rates by allocation arm allowed no major safety concerns and allowed the feasibility study to progress into the full phase III trial. <h3>Conclusion</h3> This feasibility report describes the early safety of biologic mesh placement within a novel surgical technique, paired with rapid, standardised delivery across a multicentre setting as part of a randomised trial. It shows that trainee research networks can lead and deliver complex interventional surgical trials, enabling progression to a full phase III study. <h3>Disclosure of interest</h3> None Declared.